Regen BioPharma Inc (RGBP)

[aheadofthecurve]

found this, dated Nov15 https://www.chemxpert.in/news/nanosmart-receives-second-fda-orphan-drug-designation-for-treatment-of-pediatric-cancer

From RGBP website to check to see if related
HemaXellerate
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
Fat stem cell based product to treat bone marrow that has been damaged
Bone marrow damage occurs from radiation, chemo, or chronic conditions
HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow
?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)